primary peritoneal cancer
Showing 1 - 25 of >10,000
A Prospective, Randomized Controlled Study of Cyclophosphamide,
Not yet recruiting
- Epithelial Ovarian Cancer
-
Shijiazhuang, Hebei, ChinaHebei
Aug 20, 2023
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7
Active, not recruiting
- Stage III Fallopian Tube Cancer AJCC v7
- +14 more
- Epacadostat
- +2 more
-
Minneapolis, Minnesota
- +1 more
Jan 27, 2023
Cancer, Solid Tumor, Ovarian Cancer Trial in Minneapolis (FT538, Enoblituzumab)
Not yet recruiting
- Cancer
- +4 more
- FT538
- Enoblituzumab
-
Minneapolis, MinnesotaMasonic Cancer Center - University of Minnesota
Jan 24, 2023
PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Recruiting
- PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Dec 4, 2022
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer Trial (Luveltamab tazevibulin, Pegfilgrastim)
Not yet recruiting
- Ovarian Cancer
- +4 more
- Luveltamab tazevibulin
- Pegfilgrastim
- (no location specified)
May 12, 2023
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer Trial (Cisplatin, No treatment)
Not yet recruiting
- Stage III Ovarian Cancer
- +5 more
- Cisplatin
- No treatment
- (no location specified)
Dec 12, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Houston (Paclitaxel, Carboplatin, Bevacizumab)
Recruiting
- Ovarian Cancer
- +2 more
- Paclitaxel
- +3 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 13, 2023
Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)
Recruiting
- Mucinous Ovarian Cancer
- +2 more
- Bevacizumab + modified FOLFIRINOX
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Dec 25, 2022
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +
Completed
- Epithelial Ovarian Cancer
- +2 more
- NY-ESO-1 OLP4
- +2 more
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Total Management of Ovarian Cancer
Not yet recruiting
- Tumor of Female Reproductive System
- Ovarian Cancer
- No intervention
- (no location specified)
Aug 30, 2023
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7
Active, not recruiting
- Stage III Fallopian Tube Cancer AJCC v7
- +14 more
- Carboplatin
- +4 more
-
Houston, Texas
- +4 more
Oct 20, 2022
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Denmark, Norway, Sweden (KAND567, Carboplatin)
Recruiting
- Epithelial Ovarian Cancer
- +2 more
-
Odense, Denmark
- +3 more
Oct 16, 2023
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor Trial in Pittsburgh
Not yet recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 8, 2022
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Houston (Chemotherapy, Olaparib, Therapeutic
Recruiting
- BRCA-Mutated Ovarian Carcinoma
- +30 more
- Chemotherapy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 27, 2022
Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer Trial in Houston (Paclitaxel/Bev (control), Paclitaxel/Bev + ZA
Recruiting
- Epithelial Ovarian
- +2 more
- Paclitaxel/Bev (control)
- Paclitaxel/Bev + ZA (experimental)
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate
Recruiting
- Ovarian Cancer
- +2 more
- MOv19-BBz CAR T cells
- Alpha Folate Receptor expression test
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Health System
Sep 12, 2022
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer Trial in Birmingham (mirvetuximab soravtansine (MIRV; IMGN853))
Recruiting
- Ovarian Cancer
- +2 more
- mirvetuximab soravtansine (MIRV; IMGN853)
-
Birmingham, AlabamaUniversity of Alabama at Birmingham Womens & Infants Center
Jun 30, 2022
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester
Active, not recruiting
- Fallopian Tube Clear Cell Adenocarcinoma
- +22 more
- Laboratory Biomarker Analysis
- Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
-
Rochester, MinnesotaMayo Clinic
Oct 7, 2022
Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8 Trial in
Not yet recruiting
- Stage II Fallopian Tube Cancer AJCC v8
- +33 more
- Alpha-type-1 Polarized Dendritic Cells
- Autologous Natural Killer Cell-like CTLs
-
Buffalo, New YorkRoswell Park Cancer Institute
Apr 1, 2022
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial
Recruiting
- Fallopian Tube Endometrioid Adenocarcinoma
- +32 more
- Carboplatin
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 16, 2022
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma Trial in Portland (Wee1
Not yet recruiting
- Advanced Fallopian Tube Carcinoma
- +10 more
- Wee1 Inhibitor ZN-c3
-
Portland, OregonOHSU Knight Cancer Institute
Jan 25, 2023
FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer
Completed
- FIGO Stage III and IV Ovarian Cancer
- +2 more
- ALT-803 Subcutaneous
- ALT-803 Intraperitoneal
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Oct 5, 2022
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7
Active, not recruiting
- Stage III Fallopian Tube Cancer AJCC v7
- +14 more
- Carboplatin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jun 24, 2022
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,
Active, not recruiting
- Epithelial Ovarian Cancer
- +2 more
-
New Haven, Connecticut
- +1 more
Jan 11, 2023